Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01255657 · ClinicalTrials.gov registry record · Phase 1
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
A Phase 1 study of Advanced Solid Tumors, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 3
- Study locations
NCT01255657 is a Phase 1 study of Advanced Solid Tumors that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 49 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01255657, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label study designed to determine the recommended Phase 2 dose (RPTD) and evaluate the safety and pharmacokinetics of ABT-806 in subjects with advanced solid tumors.
Conditions Studied
Interventions
- DRUG ABT-806
Study Locations (3)
Maryland
- Site Reference ID/Investigator# 54056 - Baltimore
Massachusetts
- Site Reference ID/Investigator# 41931 - Boston
Washington
- Site Reference ID/Investigator# 43422 - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01255657
The ClinicalTrials.gov registry entry for NCT01255657 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (75% lower). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ABT-806 is the first listed.
NCT01255657 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Massachusetts, Washington.
Frequently Asked Questions
What is clinical trial NCT01255657 about?
NCT01255657 is a clinical study titled "A Study of ABT-806 in Subjects With Advanced Solid Tumor Types". This is an open-label study designed to determine the recommended Phase 2 dose (RPTD) and evaluate the safety and pharmacokinetics of ABT-806 in subjects with advanced solid tumors.
What is the current status of trial NCT01255657?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2010-11. Estimated completion is 2012-11.
What conditions does trial NCT01255657 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT01255657?
The interventions under investigation include: ABT-806 (DRUG).
Who is sponsoring clinical trial NCT01255657?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01255657 being conducted?
This trial has 3 study locations across Maryland, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.